| Title: |
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice |
| Authors: |
Giannini, Edoardo G; Bucci, Laura; Garuti, Francesca; Brunacci, Matteo; Lenzi, Barbara; Valente, Matteo; Caturelli, Eugenio; Cabibbo, Giuseppe; Piscaglia, Fabio; Virdone, Roberto; Felder, Martina; Ciccarese, Francesca; Foschi, Francesco Giuseppe; Sacco, Rodolfo; Baroni, Gianluca Svegliati; Farinati, Fabio; Rapaccini, Gian Lodovico; Olivani, Andrea; Gasbarrini, Antonio; Di Marco, Maria; Morisco, Filomena; Zoli, Marco; Masotto, Alberto; Borzio, Franco; Benvegnù, Luisa; Marra, Fabio; Colecchia, Antonio; Nardone, Gerardo; Bernardi, Mauro; Trevisani, Franco |
| Contributors: |
Giannini, Edoardo G; Bucci, Laura; Garuti, Francesca; Brunacci, Matteo; Lenzi, Barbara; Valente, Matteo; Caturelli, Eugenio; Cabibbo, Giuseppe; Piscaglia, Fabio; Virdone, Roberto; Felder, Martina; Ciccarese, Francesca; Foschi, Francesco Giuseppe; Sacco, Rodolfo; Baroni, Gianluca Svegliati; Farinati, Fabio; Rapaccini, Gian Lodovico; Olivani, Andrea; Gasbarrini, Antonio; Di Marco, Maria; Morisco, Filomena; Zoli, Marco; Masotto, Alberto; Borzio, Franco; Benvegnù, Luisa; Marra, Fabio; Colecchia, Antonio; Nardone, Gerardo; Bernardi, Mauro; Trevisani, Franco |
| Publication Year: |
2018 |
| Collection: |
Padua Research Archive (IRIS - Università degli Studi di Padova) |
| Subject Terms: |
Liver cancer; advanced stage; sorafenib; survival; therapy |
| Description: |
The Barcelona Clinic Liver Cancer advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a heterogeneous population, where sorafenib alone is the recommended treatment. In this study our aim was to assess treatment and overall survival (OS) of BCLC C patients sub-classified according to clinical features (Performance Status [PS], macro-vascular invasion [MVI], extra-hepatic spread [EHS] or MVI+EHS) determining their allocation to this stage. From the Italian Liver Cancer database, we analysed 835 consecutive BCLC C patients diagnosed between 2008 and 2014. Patients were sub-classified as: PS1 alone (n=385, 46.1%), PS2 alone (n=146, 17.5%), MVI (n=224, 26.8%), EHS (n=51, 6.1%) and MVI+EHS (n=29, 3.5%). MVI, EHS and MVI+EHS patients had larger and multifocal/massive HCCs and higher alpha-fetoprotein levels than PS1 and PS2 patients. Median OS significantly declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months) and MVI+EHS (3.1 months) (P |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/29159910; info:eu-repo/semantics/altIdentifier/wos/WOS:000430388500016; volume:67; issue:5; firstpage:1784; lastpage:1796; numberofpages:13; journal:HEPATOLOGY; https://hdl.handle.net/11577/3252803 |
| DOI: |
10.1002/hep.29668 |
| Availability: |
https://hdl.handle.net/11577/3252803; https://doi.org/10.1002/hep.29668 |
| Rights: |
info:eu-repo/semantics/openAccess ; license:Accesso libero |
| Accession Number: |
edsbas.BB285F4D |
| Database: |
BASE |